Obsolete immunologic drugs, part 1

Hospital Pharmacy

Volumn 32, Issue 3, 1997, Pages 348-358

  Grabenstein, John D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

A VEE 11; AMBOTOXOID; ANTISERUM; BACTERIAL VACCINE; COLO LYSATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; GONO YATREN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN; INACTIVATED VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PSEUDOMONAS LIPOPOLYSACCHARIDE; QUADRIGEN; REAGENT; RICKETTSIA VACCINE; STAPHYLOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; TUBERCULIN; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ACNE; ANTHRAX; ARTHRITIS; BACTERIAL INFECTION; BRUCELLOSIS; DIPHTHERIA; DYSENTERY; ERYSIPELAS; GAS GANGRENE; GONORRHEA; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LEPTOSPIROSIS; MENINGITIS; MENINGOCOCCOSIS; ORAL DRUG ADMINISTRATION; REVIEW; RICKETTSIOSIS; ROCKY MOUNTAIN SPOTTED FEVER; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TETANUS; TUBERCULOSIS; TULAREMIA; TYPHOID FEVER; TYPHUS;

EID: 0030891464     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Grabenstein JD. ImmunoFacts: Vaccines and Immunologic Drugs. St. Louis: Facts and Comparisons, November 1996.
2. Wilson CO, Jones TE, eds. American Drug Index. 1st ed. Philadelphia: JB Lippincott; 1956.
3. Billups NF, ed. American Drug Index. 21st ed. Philadelphia: JB Lippincott; 1977.
4. Gutman J, ed. Modern Drug Encyclopedia and Therapeutic Index. 1st ed. New York: Hoeber, Inc.; 1934.
5. American Medical Association. New and Nonofficial Remedies. Chicago: American Medical Association; 1922.
6. American Medical Association. New and Nonofficial Drugs. Philadelphia: JB Lippincott Co.; 1958.
7. American Medical Association. AMA Drug Evaluations. 1st ed. Chicago: American Medical Association; 1971.
8. United States Pharmacopeial Convention. Pharmacopeia of the United States. 9th ed. Philadelphia: JB Lippincott; 1916.
9. Jones JM, ed. Physicians' Desk Reference to Pharmaceutical Specialties and Biologicals. 1st ed. Rutherford, NJ: Medical Economics, Inc.; 1947.
10. Cook EF, LaWall CH, eds. Remington's Practice of Pharmacy. 7th ed. Philadelphia: JB Lippincott; 1926.
11. Wood HC Jr., LaWall CH, Youngken HW, Osol A, Griffith I, Gershenfeld L. United States Dispensatory. Philadelphia: JB Lippincott; 1937.
12. Sherman GH. Vaccine Therapy in General Practice. Detroit: GH Sherman; 1916.
13. Sherman GH. A Physician's Manual of Vaccine Therapy. Detroit: GH Sherman; 1924.
14. Galambos L, Sewell JE. Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-95. New York: Cambridge University Press; 1995.
15. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 1996;2:1-11.
16. Ricketts HT, Dick GE Infection, Immunity and Serum Therapy: In Relation to the Infectious Diseases of Man. 2nd ed. Chicago:AMA Press; 1913.
17. Parish HJ. Antisera, Toxoids, Vaccines and Tuberculins in Prophylaxis and Treatment. 3rd ed. Baltimore: Williams & Wilkins; 1954.
18. Parish HJ. A History of Immunizations. Baltimore: Williams & Wilkins; 1965, 108.
19. Kolmer JA, Tuft L. Clinical Immunology, Biotherapy and Chemotherapy. Philadelphia: WB Saunders; 1941.
20. Parke, Davis & Company. The Treatment of Rheumatic Infections. Detroit: Parke, Davis & Company; 1913.
21. Burke DS. Vaccine therapy for HIV:A historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. Vaccine. 1993;11:883-891.
22. Beerman H, Ingraham NR Jr. Intradermal tests in the diagnosis of certain infectious diseases. Am J Med Sci. 1950;220:435-463.
23. Baer RL, Yanowitz M. Skin tests in various infectious and parasitic diseases:A summary in table form. Arch Dermat Syphil. 1950;62:491-501.
24. Food & Drug Administration. Skin test antigens; proposed implementation of efficacy review. Fed Reg. 1977;42: 52674-52723, 61613.
25. Food & Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Fed Reg. 1985;50:51002-51117.
26. Alexander HE. Experimental basis for treatment of Haemophilus influenzae infections. Am J Dis Child. 1943;66: 160-172.
27. Santosham M, Reid R, Ambrosino DM, Wolff MC, Almeido-Hill J, Priehs C, Aspery KM, Garrett S, Croll L, Foster S, Burge G, Page P, Zacher B, Moxon R, Siber GR. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med. 1987;317:923-929.
28. Hoyne AL. Intravenous treatment of meningococcic meningitis with meningococcus antitoxin. JAMA. 1936;107: 478-481.
29. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med. 1913;17: 553-576.
30. Felton LD. The units of protective antibody in anti-pneumococcus serum and antibody solution. J Infect Dis. 1928;43: 531-542.
31. Bullowa JGM. The reliability of sputum typing and its relation to serum therapy. JAMA. 1935;105:1512-1518.
32. Dowling HF, Abernethy TJ. The treatment of pneumococcus pneumonia: A comparison of the results obtained with specific serum and with sulfapyridine. Am J Med Sci. 1940;199:55-62.
33. Product information on Pneumococcus polysaccharides (ER Squibb). In: Physicians' Desk Reference. Rutherford, NJ: Medical Economics, Inc.; 1949, 477.
34. English PC. Therapeutic strategies to combat pneumococcal disease: Repeated failure of physicians to adopt pneumococcal vaccine, 1900-1945. Perspect Biol Med. 1987;30:170-185.
35. Food & Drug Administration. Bacterial vaccines and bacterial antigens with no U.S. standard of potency: Implementation of efficacy review. Fed Reg. 1977;42: 58266-58318.
36. Grabenstein JD. The research pipeline: 3. Investigational vaccines for "uncommon" diseases. Hosp Pharm. 1994;29:282-288.
37. Wilde H, Thipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: Perspectives on a worldwide crisis. Ann Intern Med. 1996;125:233-236.
38. Food & Drug Administration. Bacterial vaccines and bacterial antigens with "No U.S. Standard of Potency." Fed Reg. 1979;44:1544-1549.
39. Keating P. Vaccine therapy and the problem of opsonins. J Hist Med Allied Sci. 1988;43:275-296.
40. Eli Lilly & Company. Immunizing Biologicals. Indianapolis: Eli Lilly & Company; 1957.
41. Eaton MD, Bayne-Jones S. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA. 1934;103:1769-1776,1847-1853,1934-19 39.
42. Kreuzer KN. Bacteriophages. In: Joklik WK, Willett HP, Amos DB, Wilfert CM, eds. Zinsser Microbiology. 19th ed. Norwalk, CT: Appleton & Lange; 1988, 757-772.
43. Lyon BBV. A consideration of autogenous vaccines. J Am Pharm Assoc. 1914;3:721-729.
44. Smith DT, Conant NF, Willett HP. Zinsser Microbiology. 14th ed. New York: Appleton-Century-Crofts; 1968, 463-465.
45. Food & Drug Administration. Viral and rickettsial vaccines; proposed implementation of efficacy review. Fed Reg. 1980;45:25652-25758.
46. Centers for Disease Control. Production of typhus vaccine discontinued in the United States. MMWR. 1980;29:465.